Amryt Pharma Plc
(NASDAQ : AMYT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.23%177.110.7%$1337.30m
MRKMerck & Co., Inc. -0.08%91.100.7%$1166.93m
PFEPfizer Inc. -1.78%51.500.9%$1093.93m
LLYEli Lilly & Co. -1.61%319.021.1%$1028.87m
BMYBristol-Myers Squibb Co. -1.52%75.831.0%$992.55m
ABBVAbbVie, Inc. -1.08%151.501.9%$948.34m
AZNAstraZeneca Plc -1.56%65.041.0%$434.60m
SGENSeagen Inc. 0.66%178.115.7%$317.98m
TPTXTurning Point Therapeutics, Inc. -0.11%75.170.0%$287.77m
GSKGSK Plc -0.60%43.270.2%$274.80m
NVSNovartis AG -1.36%83.380.2%$162.33m
HZNPHorizon Therapeutics Plc -0.33%79.505.4%$161.28m
MRTXMirati Therapeutics, Inc. 3.35%69.381.6%$151.62m
ALNYAlnylam Pharmaceuticals, Inc. 0.99%147.298.1%$141.90m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.30%145.270.0%$141.89m

Company Profile

Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded by Joseph Amrit Wiley and Rory Peter Nealon on August 28, 2015 and is headquartered in Dublin, Ireland.